Filing Overview
Haymaker Acquisition Corp. III filed this Form 8-K on March 30, 2022, reporting an event dated March 29, 2022. The filing relates to the proposed business combination with BioTE Holdings, LLC and associated parties. It includes an analyst day presentation prepared for the March 29, 2022 analyst day.
Business Context and Reporting Period
The transaction is intended to combine Haymaker Acquisition Corp. III, a special purpose acquisition company, with BioTE. The filing does not report a quarterly or annual operating period and does not provide historical financial statements.
Key Financial Metrics
- Revenue, profit, cash flow and margins: The filing text does not provide clear values.
- Debt and liquidity: The filing references anticipated transaction cash proceeds, minimum cash requirements after potential shareholder redemptions, and proposed Truist debt financing, but provides no clear amounts.
- Other metrics: The filing text does not provide clear operating or valuation metrics. The attached analyst day presentation may contain additional information, but its contents are not included in the supplied filing text.
Material Changes Versus Prior Period
No period-over-period financial comparison is presented. The principal disclosed development is the preparation and release of analyst day materials concerning the proposed business combination.
Guidance, Outlook, Risks and Unusual Items
The filing contains forward-looking statements regarding the transaction, expected transaction benefits, growth, operating performance, capital expenditures, competitive advantages, business prospects and future plans. These statements are subject to substantial risks, including failure to complete the transaction, failure to satisfy shareholder approval and minimum-cash conditions, inability to obtain regulatory approvals, termination of the agreement, shareholder redemptions, inability to complete Truist debt financing, transaction costs, failure to realize projected benefits, and potential loss of exchange listing.
Additional risks identified include competition, regulatory and pharmacy-compounding scrutiny, supply-chain disruption, COVID-19-related market downturns, data privacy and cybersecurity, litigation, intellectual property, healthcare fraud and abuse, HIPAA compliance, physician and employee relationships, reliance on third-party manufacturers, capital requirements, potential dilution, and risks associated with BioTE’s limited operating history and nutraceutical business.
The analyst day presentation is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing is also not a proxy statement or an offer to sell securities. Stockholders are directed to the preliminary and definitive proxy statements for complete transaction information.
Important Facts to Verify
- Review the analyst day presentation, preliminary proxy statement and definitive proxy statement for BioTE’s financial results, forecasts, valuation and transaction terms.
- Verify the proposed transaction’s required shareholder approval, regulatory approvals and minimum cash condition after redemptions.
- Confirm the availability and final terms of the contemplated Truist debt financing.
- Assess projected transaction benefits, estimated redemptions, dilution and post-transaction capitalization.
- Review the detailed risk factors concerning BioTE’s regulatory environment, supply chain, litigation, cybersecurity, competition and need for additional capital.